Daiichi Sankyo’s Datroway Receives the MHLW’s Approval for Unresectable or Recurrent HR+/HER2- Breast Cancer
Shots:
- The Japanese MHLW has approved Datroway (datopotamab deruxtecan) for treating adults with HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after previous CT. Reviews in the US, EU, China & other regions are underway
- Approval was based on P-III (TROPION-Breast01) study assessing the safety & efficacy of Datroway (6mg/kg, IV, Q21D) vs single-agent CT (eribulin, capecitabine, vinorelbine or gemcitabine) in adults (n=732) with HR+/HER2- metastatic breast cancer
- Study showed a 37% reduction in the disease progression or death risk, with mPFS of 6.9mos. vs 4.9mos.
f: Daiichi Sankyo | Image: Daiichi Sankyo
Related News:- Daiichi Sankyo Reports Pooled Analysis from TROPION-Lung05 & TROPION-Lung01 Trials of Datopotamab Deruxtecan (Dato-DXd) for NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
